Servier Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.77 M
- Company Age 26 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 14.16%
- Ebitda 89.85%
- Net Worth -12.63%
- Total Assets -18.41%
About Servier Pharmaceuticals (India)
Servier Pharmaceuticals (India) Private Limited (SPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 September 1998 and has a history of 26 years and four months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.77 M, as per Ministry of Corporate Affairs (MCA) records.
Pierre Andriot, Jean Thomas, and Aurelien Breton serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U51397MH1998PTC116694
-
Company No.
116694
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Sep 1998
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Servier Pharmaceuticals (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pierre Andriot
|
Director | 18-Dec-2013 | Current |
|
Jean Thomas
|
Director | 15-Jan-2020 | Current |
| Aurelien Breton | Director | 23-Sep-2024 | Current |
Financial Performance of Servier Pharmaceuticals (India).
Servier Pharmaceuticals (India) Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 14.16% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Servier Pharmaceuticals (India)?
In 2020, Servier Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Servier India Private LimitedPierre Andriot and Aurelien Breton are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Servier Pharmaceuticals (India)?
Unlock and access historical data on people associated with Servier Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Servier Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Servier Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
